ArticleVaccines2026
Longitudinal Assessment of an 800 µg Dose of HEBERSaVax in Non-Human Primates over Six Months.
Article in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesHEBERSaVax is a therapeutic cancer vaccine based on recombinant human VEGF antigen adjuvated with VSSP or Aluminum Phosphate (AP). Clinical trials demonstrated the vaccine's safety and tolerability, with predominantly mild to moderate (grade 1-2) local adverse events. Initial dose optimization studies using the VSSP (Center of Molecular Immunology (CIM), Havana, Cuba) adjuvant showed that increasing the antigen dose to 800 μg significantly enhanced immunogenicity, as measured by improved seroconversion rates, stronger blockade of VEGF/VEGFR1-2 interactions, and reduced platelet-derived VEGF levels.
methodsThe AP adjuvant was used to perform essential preclinical validation in non-human primates to support the transition of the 800 μg antigen dose to Phase II clinical trials (CENTAURO-4 and CENTAURO-6).
resultsHEBERSaVax adjuvated with AP induced: (1) robust humoral responses with high-titer anti-VEGF antibodies (peak 1:15,000), (2) functional biological activity, specifically the suppression of VEGF-mediated signal transduction, in 90% (9/10 animals), and (3) measurable cellular immune responses. All immunogenic effects were achieved without evidence of systemic toxicity, confirming the safety profile of this preparation.
conclusionsThese findings provide compelling preclinical evidence that the 800 μg HEBERSaVax/AP combination maintains the immunogenic potential previously observed with VSSP while demonstrating an equally favorable safety profile. The results strongly support continued clinical development of this VEGF-targeted immunotherapy for cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.